Duloxetine in the treatment of generalized anxiety disorder

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 6, 2008, Pages 1169-1180

  Norman, Trevor R ^a   Olver, James S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Duloxetine; Generalized anxiety disorder; Hamilton anxiety rating scale; Psycho social function; Withdrawal syndrome

Indexed keywords

DULOXETINE; PLACEBO; VENLAFAXINE;

ABNORMAL DREAMING; ANXIETY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ERECTILE DYSFUNCTION; EVENING DOSAGE; FATIGUE; GENERALIZED ANXIETY DISORDER; HEART RATE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; LIBIDO DISORDER; LONG TERM CARE; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; QT INTERVAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 60249099901     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Allgulander C, Hartford J, Russell J. 2007. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin, 23:1245-52.
2. Allgulander C, Nutt D, Detke M, et al. 2008. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol, 22:417-25.
3. Anderson I. 2006. The new guidelines from the British Association for Psychopharmacology for anxiety disorders. Int J Psychiatr Clin Pract, 10:10-7.
4. Baldwin DS. 2006. Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders. Int J Psychiatr Clin Pract, 10:12-5.
5. Baldwin DS, Polkinghom C. 2005. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol, 8:293-302.
6. Ballenger JC. 2001. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry, 62:11-9.
7. Borsini F, Podhorma J, Marazzitti D. 2002. Do animal models of anxiety predict anxiolytic-like effects of antidepressants. Psychopharmacology, 163:121-41.
8. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. 2001. Comparative affinity of duloxetine and venlafaxine for semtonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology, 25:871-80.
9. Bymaster FP, Lee TC, Knadler MP, et al. 2005. The dual transport inhibitor duloxetine: A review of its preclinical pharmacology, pharmacokinetic profile and clinical results in depression. Curr Pharm Des, 11:1475-93.
10. Carter RM, Wittchen H-U, Pfisster H, et al. 2001. One-year prevalence of subthreshold and threshold DSM-IV generalised anxiety disorder in a nationally representative sample. Depress Anxiety, 13:78-88.
11. Chan C, Yeo KP, Pan AX, et al. 2007. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. Br J Clin Pharmacol, 63:310-14.
12. Davidson JR. 2001. Pharmacotherapy of generalised anxiety disorder. J Clin Psychiatry, 62(Suppl 11):46-50.
13. Davidson JR, Allqulander C, Pollack MH, et al. 2008. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol, 23:519-23.
14. Dunner DL, Goldstein DJ, Mallinckrodt C, et al. 2003. Duloxetine in the treatment of anxiety symptoms associated with depression. Depress Anxiety, 18:53-61.
15. Durham R, Chambers JA, Power KG, et al. 2005. Long-term outcome of cognitive behaviour therapy clinical trials in Scotland. Health Technol Assess, 9:1-174.
16. Durham RC, Murphy T, Allan T, et al. 1994. Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder. Br J Psychiatry, 165:315-23.
17. EMEA. ICH Topic E9: Statistical principles for clinical trials (CPMP/ICH/ 363/96), 1998.
18. Endicott J, Russell JW, Raskin J, et al. 2007. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: Three independent studies. J Clin Psychiatry, 68:518-24.
19. Engleman ES, Perry KW, Mayle DA, et al. 1995. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology, 12:287-95.
20. Fermini B, Fossa AA. 2003. The impact of drug-induced QT interval prolongation on drug discovery. Nat Rev Drug Discov, 2:439-47.
21. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin, 23:175-84.
22. Goldstein DJ, Lu Y, Detke MJ, et al. 2004. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine, J Clin Psychopharmacol, 24:389-99.
23. Goldstein DJ, Mallinckrodt C, Lu Y, et al. 2002. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry, 63:225.
24. Gorman JM. Treatment of generalized anxiety disorder, J Clin Psychiatry, 63:17-23.
25. Gould RA, Otto MW, Pollack MH, et al. 1997. Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary recta-analysis. Behav Res Ther, 28:285-305.
26. Healy D, Cattell D. 2003. Interface between authorship, industry and science in the domain of therapeutics. Br J Psychiatry, 183:22-7.
27. Hidalgo RB, Tupler LA, Davidson JRT. 2007. An effect size analysis of pharmacologic treatments for generalised anxiety disorder. J Psychopharmacol, 21:864-72.
28. Hudson JI, Wohlreich MM, Kajdasz DK. 2005. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol, 20:327-41.
29. Kasamo K, Blier P, de Montigny C. 1996. Blockade of serotonin and norepininephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther, 277:278-86.
30. Kessler RC, Chiu TW, Demler O, et al. 2005. Prevalence, severity and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62:617-27.
31. Kingdon D, Tyrer P, Seivewright N, et al. 1996. The Nottingham Study of Neurotic Disorder: influence of cognitive therapists on outcome. Br J Psychiatry, 169:93-7.
32. Koponen H, Allgulander C, Erickson J, et al. 2007. Efficacy of duloxetine for the treatment of generalized anxiety disorder: Implications for primary physicians. Prim Care Companion J Clin Psychiatry, 9:100-7.
33. Lam RW. 2006. Generalized anxiety disorder: how to treat and for how long? Int J Psychiatr Clin Pract, 10:10-15.
34. Lantz RJ, Gillespie TA, Rash TJ, et al. 2003. Metabolism, excretion and pharmacokinetics ofduloxetine in healthy human subjects. Drug Metab Dispos, 31:1142-50.
35. Lieb R, Becker E, Altamura C. 2005. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol, 15:445-52.
36. Lieb R, Isenee B, von Sydow K, et al. 2000. The early stages of psychopathology study (EDSP), a methodological update. Eur Addict Res, 6:170-82.
37. NICE. Clinical Guideline 22. 2004. Anxiety: Management of anxiety (panic disorder, with or without agoraphobia and generalised anxiety disorder) in adults in primary, secondary and community care. URL: www.nice. orh.uk/CG022NICEguideline.
38. Nicolini H, Bakish D, Duenas H, et al. 2008. Improvements of psychic and somatic symptoms in adult patients with genearalised anxiety disorder: examination froma a duloxetine, venlafaxine extended release and placebo trial. Psychol Med, doi:10.1017/S0033291708003401.
39. Parikh AR, Thatcher BT, Tamano EA. 2008. Suicidal ideation associated with duloxetine use. J Clin Psychopharmacol, 28:101-2.
40. Perlis RH, Perlis CS, Wu Y, et al. 2005. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry, 162:1957-60.
41. Rynn M, Russell J, Erickson J, et al. 2007. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: A flexible dose, progressive-titration, placebo controlled trial. Depress Anxiety, 22:1-8.
42. Shader RI, Greenblatt DJ. 1993. Use ofbenzodiazepines in anxiety disorders. N Engl J Med, 328:1398-405.
43. Sharma A, Goldberg MJ, Cerimele BJ. 2000. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol, 40:161-7.
44. Skinner MH, Kuan Han-Yi, Skerjanec A, et al. 2003. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol, 57:54-61.
45. Skinner MH, Skerjanec A, Seger M, et al. 2000. The effect of food and bedtime administration on duloxetine pharmacokinetics. Clin Pharmacol Ther, 67:129.
46. Stahl SM, Grady MM, Moret C, et al. 2005. SNRIs: Their pharmacology, clinical efficacy and tolerability in comparison with other classes of antidepressants. CNS Spectr, 10:732-47.
47. Suri A, Reddy S, Gonzales C, et al. 2005. Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Int J Clin Pharmacol Ther, 43:78-84.
48. Tianmei S, Knadler MP, Lim MT, et al. 2007. Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. Clin Pharmacokinet, 46:767-5.
49. Troelsen KB, Nielsen EO, Mirza NR. 2005. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology, 181:741-50.
50. Turcotte JE, Debonnel G, de Montigny C, et al. 2001. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology, 24:511-21.
51. Turner EH, Matthews AM, Lindardatos E, et al. 2008. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med, 358:252-60.
52. Tyrer P, Baldwin D. 2006. Generalised anxiety disorder. Lancet, 368:2156-64.
53. Vincent S, Bieck PR, Garland EM, et al. 2004. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation, 109:3202-7. Wemicke J, Lledo A, Raskin , I, et al. 2007. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf, 30:437-55.
54. Wittchen H-U, Carter RM, Pfisster H, et al. 2000. Disabilities and quality of life in pure and co-morbid generalised anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol, 15:319-28.
55. Wittchen H-U, Nelson CB, Lachner G. 1998. Prevalence of mental disorders and psychosocial impairment in adolescents and young adults. Psychol Med, 28:109-26.
56. Wohlreich MM, Mallinckrodt CH, Prakash A, et al. 2007. Duloxetine for the treatment of major depressive diosrder: safety and tolerability associated with dose escalation. Depress Anxiety, 24:41-52.
57. Wong DT. 1998. Duloxetine (LY248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp Opin Investig Drugs, 7:1-9.
58. Yonkers KA, Dyck IR, Warshaw M, et al. 2000. Factors prediciting the course of generalised anxiety disorder. Br J Psychiatry, 176:544-9.
59. Zhang L, Chappell J, Gonzales CR, et al. 2007. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol, 49:146-53.